| Company type | Non-profit |
|---|---|
| Founded | 1994 in Cambridge, MA |
| Founder | William W. Li, MD and Vincent W. Li, MD (co-founders) |
| Headquarters | Cambridge, MA, U.S. |
| Revenue | 1,772,286 United States dollar (2017)  |
| Total assets | 359,298 United States dollar (2022) |
| Website | angio.org |
The Angiogenesis Foundation, is a United States 501(c)(3) nonprofit organization established in 1994 for the study of angiogenesis. The foundation developed a therapy for canine cancer, called the Navy Protocol. This treatment works by starving the tumor of its blood supply. In 2004, they helped publicly launch the first antiangiogenic therapy for cancer, bevacizumab, starting with colorectal cancer.
Co-founder Dr. William Li won the 2024 Dr. Andrew von Eschenbach Award for his work in angiogenesis.
References
- Dog's tale of survival opens door in cancer research, July 24, 2002
- Colon cancer drug seen as long awaited victory, February 26, 2004
- The Angiogenesis Foundation Chief Executive Officer Dr. William Li Was Honored As the Inaugural Recipient of the Dr. Andrew Von Eschenbach Award
External links
- Official website
- "The Angiogenesis Foundation Receives Highest Rating from Charity Navigator" - The Providence Journal, Nov. 7, 2013.
 | This article about a medical organization or association is a stub. You can help Misplaced Pages by expanding it. |